Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Buy” by Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned an average rating of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $62.50.

Several research firms have recently commented on JSPR. JMP Securities reiterated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Royal Bank of Canada dropped their price target on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. Finally, UBS Group initiated coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $38.00 price target on the stock.

Jasper Therapeutics Trading Down 1.9 %

Jasper Therapeutics stock opened at $5.21 on Monday. The stock has a market cap of $78.26 million, a P/E ratio of -1.10 and a beta of 2.23. The stock has a 50 day moving average of $5.79 and a 200-day moving average of $15.30. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, equities analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its position in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after buying an additional 1,698 shares during the period. MetLife Investment Management LLC increased its holdings in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter valued at $223,000. Finally, Tema Etfs LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter valued at $266,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.